COMPREHENSIVE DOSE-FINDING STRATEGY FOR SINGLE-AGENT RP-3500, A HIGHLY SELECTIVE INHIBITOR OF ATAXIA TELANGIECTASIA AND RAD3-RELATED (ATR) KINASE

Elisa Fontana,1 Elizabeth Lee,2 Ezra Rosen,3 David R. Spigel,4 Martin Højgaard,5 Stephanie Lheureux,6 Niharika Mettu,7 Louise Carter,8 Ruth Plummer,9 Peter Manley,10 Danielle Ulanet,10 Victoria Rimkunas,10 Ian M. Silverman,10 Joseph O’Connell,10 Robin McDougall,10 Marisa Wainszelbaum,10 Yi Xu,10 Maria Koehler,10 Adrian J. Fretland,10 Timothy A. Yap11

1Sarah Cannon Research Institute UK, London, UK, 2Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, 3Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 4Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA, 5Rigshospitalet, Department of Oncology, Copenhagen, Denmark, 6Princess Margaret Cancer Centre - Toronto, Canada, 7Duke University, Medical Oncology, Durham, NC, USA, 8Division of Cancer Sciences, University of Manchester and the Christie NHS Foundation Trust Manchester, UK, 9Newcastle University and Newcastle Hospitals NHS Foundation Trust, Northern Centre for Cancer Care, Newcastle-upon-Tyne, UK, 10Repare Therapeutics, Cambridge, MA, USA, 11Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
DECLARATION OF INTERESTS

I have the following financial relationships to disclose:

- Employment - Hospital Corporation of America (HCA) International
The phase 1/2a TRESR study (NCT04497116) evaluated RP-3500, a potent and highly selective ATR inhibitor (ATRi), in patients with advanced solid tumors harboring ATRi-sensitizing mutations.

- TRESR phase 1 study of RP-3500 monotherapy enrolled 120 patients between July 2020 and October 2021; enrollment into phase 2 is ongoing.

- Interim data on safety and efficacy were presented at the ANE meeting in Boston (Oct. 2021).

- A comprehensive approach to dose and schedule selection included pharmacokinetic/pharmacodynamic and safety analyses from three dosing cohorts at therapeutic doses (N=85):
  - 120mg once daily, 3 days on/4 days off, (n=25)
  - 160mg once daily, 3 days on/4 days off, (n=34)
  - 160mg once daily, 3 days on/4 days off, 2 weeks on/1 week off (n=26)

- A dosing nomogram was developed based on data to predict toxicity responses.
### COMPREHENSIVE DOSE FINDING STRATEGY IN THE PHASE 1 TRESR STUDY

<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>160 mg, QD (5d on/2d off)</td>
<td>3 pts (0 DLT)</td>
</tr>
<tr>
<td>200 mg, QD (3d on/4d off, 2wks on/1 wk off)</td>
<td>34 pts (2 DLT)</td>
</tr>
<tr>
<td>160 mg, QD (3d on/4d off)</td>
<td>3 pts (2 DLT)</td>
</tr>
<tr>
<td>160 mg, QD (3d on/4d off, 2wks on/1 wk off)</td>
<td>G3 anemia</td>
</tr>
<tr>
<td>120 mg, QD (5d on/2d off)</td>
<td>26 pts (2 DLT)</td>
</tr>
<tr>
<td>120 mg, QD (3d on/4d off, 2wks on/1 wk off)</td>
<td>G3 anemia/ neutrophils</td>
</tr>
<tr>
<td>100 mg, QD (5d on/2d off)</td>
<td>G3 anemia, G3/4 platelets</td>
</tr>
<tr>
<td>120 mg, QD (3d on/4d off)</td>
<td>25 pts (0 DLT)</td>
</tr>
<tr>
<td>40/60 mg, BID (3d on/4d off)</td>
<td>5 pts (3 eval) (1 DLT)</td>
</tr>
<tr>
<td>40/80 mg, BID (5d on/2d off)</td>
<td>G3 platelets</td>
</tr>
<tr>
<td>5–80 mg, QD (5d on/2d off)</td>
<td>Not tolerated in DLT period or later</td>
</tr>
</tbody>
</table>

*2 additional patients enrolled at the 200 QD dose level were not evaluated at this dose level as they were switched to 160 QD early in Cycle 1, following the DLTs in the other 2 subjects

Dose selection was guided by drug exposure analyses, target engagement, and tolerability during C1 and beyond.

---

**Elisa Fontana**

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
TREATMENT-RELATED AEs BY DOSE LEVEL AND GRADE (≥10% IN ANY ARM)

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; GI, gastrointestinal; Haem, haematological; QD, once daily; wks, weeks.
TREATMENT-RELATED AEs ≥10% BY GRADE ARE SIMILAR BY DOSE LEVEL

- **160 mg QD, 3 d on/4 d off**
- **120 mg QD, 3 d on/4 d off**
- **160 mg QD, 3 d on/4 d off, 2 wk on/1 wk off**

AE, adverse event; QD, once daily; wks, weeks.
# DOSE MODIFICATIONS AND TRANSFUSIONS

<table>
<thead>
<tr>
<th></th>
<th>120 mg: 3 d on/4 d off</th>
<th>160 mg: 3 d on/4 d off</th>
<th>160 mg: 3 d on/4 d off</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N=25)</td>
<td>(N=34)</td>
<td>(N=26)</td>
</tr>
<tr>
<td>Cycles completed:</td>
<td>3 (1-9)</td>
<td>2 (0-12)</td>
<td>2 (0-8)</td>
</tr>
<tr>
<td>median (range)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients exposed to RP-3500 n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥1 cycle</td>
<td>25 (100)</td>
<td>31 (91.2)</td>
<td>23 (88.5)</td>
</tr>
<tr>
<td>≥2 cycle</td>
<td>19 (76.0)</td>
<td>21 (61.8)</td>
<td>17 (65.4)</td>
</tr>
<tr>
<td>Interruptions (related to AE) n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>6 (24.0)</td>
<td>4 (11.8)</td>
<td>4 (15.4)</td>
</tr>
<tr>
<td>2</td>
<td>3 (12.0)</td>
<td>4 (11.8)</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>≥3</td>
<td>3 (12.0)</td>
<td>0</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>Dose reductions (related to AE), n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3 (12.0)</td>
<td>6 (17.6)</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>2</td>
<td>1 (4.0)</td>
<td>0</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>RBC transfusions, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cycle 1</td>
<td>2 (8.0)</td>
<td>2 (5.9)</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>Cycles 1-2</td>
<td>3 (12.0)</td>
<td>6 (17.6)</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>Cycles 1-3+</td>
<td>4 (16.0)</td>
<td>11 (32.4)</td>
<td>2 (7.7)</td>
</tr>
</tbody>
</table>

AE, adverse event; d, day; RBC, red blood cell; wk, week.

---

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
ctDNA DEMONSTRATES DRUG ACTIVITY ACROSS DOSING COHORTS

Changes at cycle 2 relative to baseline
- Response: ≤ -50%
- Stable: > -50% and ≤ +50%
- Progression: > +50%

ctDNA Dynamics

ANEMIA NOMOGRAM: A TOOL TO PREDICT EARLY DOSE MODIFICATIONS

Predicted Hb(Day) ~ HB_{Baseline} − Decay Rate * Day

Known Parameter

Predicted Parameter based on ~D7 hematology

Multivariable prediction of Hb decrease

Day 21 ± 3

R2 ~ 0.82

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
SUMMARY AND CONCLUSIONS

- This comprehensive safety analysis of 3 dosing schedules of RP-3500 monotherapy confirmed the acceptable tolerability of the recommended phase 2 dose (160mg 3 days/4 days off).

- Anemia was the most common reported toxicity.

- A dose modification plan that includes 2 alternative dosing schedules was established to mitigate the on-target toxicity of anemia and maintain patients on an efficacious RP-3500 dosing schedule.

- Based on surrogate efficacy estimation by on-treatment ctDNA decline the doses expected to be comparable in terms of efficacy.

- A nomogram based on changes in monocytes and hemoglobin levels in cycle 1 is being prospectively evaluated to identify patients at increased risk of hemoglobin decrease at the initial dose/schedule and help reduce the need for dose holds or transfusions.
ACKNOWLEDGMENTS

- The authors would like to thank the patients, their families, and all investigators involved in this study.

- Participating TRESR Sites for their work and contribution
  - Billy Hoadley; Christian Brown; Sandra Montez - University of Texas MD Anderson Cancer Center
  - Mary Liebers; Ava Greenberg - Dana Farber Cancer Institute
  - Isabella Schafer - Sarah Cannon Research Institute/Tennessee Oncology
  - Arousia Kazarian - Memorial Sloan Kettering Cancer Center
  - Paula Lee - Duke Cancer Institute
  - Jocelyn Hubbard - Massachusetts General Hospital
  - Brenton Travers; Victoria Nelson - Rhode Island Hospital/Lifespan
  - Rachel Wildman; Ashley Adile - Princess Margaret Cancer Center
  - Terry Wood; Prerana Huddar - The Christie NHS Foundation Trust, UK
  - Helen (Blair) Porteous - Newcastle Hospital NHS Foundation Trust, UK
  - Saba Mahmud; Paul Rigby - Sarah Cannon Research Institute UK
  - Cecilia Sonander Westphal; Emma-Sofie Sonderskov Darre - Righospitalet, Denmark

- Precision Oncology Decision Support (PODS) Group at the University of Texas MD Anderson Cancer Center

- The authors would like to thank Hitesh Mistry, Systems Forecasting for his thoughts and input on the nomogram.

- The Repare Clinical Study Team
  - Livia Gjylameti, Danielle Ulanet, Parham Nejad, Suzanne May, Peter Manley, Marisa Wainszelbaum, Biljana Bazdar-Vinovrski, Stephanie Guerrera, Joseph O’Connell, Victoria Rimkunas, Ian Silverman, Adrian Fretland, and Maria Koehler

- ProPharma Group, Clinical Research Organization (CRO)

- This study was funded by Repare Therapeutics
Thank You!

European Society for Medical Oncology (ESMO)
Via Ginevra 4, CH-6900 Lugano
T. +41 (0)91 973 19 00
esmo@esmo.org